In our weekly expert view piece, Darren Cooper, director of industry solutions at Stibo Systems examines the implications and potential benefits of the Indentification and Medicinal Products (IDMP) standards.
As regulations continue to evolve, the pharmaceutical industry is faced with a series of new demands as it manages information to meet increasing challenges.
Designed to support the unique identification and exchange of regulated information, the recent introduction of Identification of Medicinal Products (IDMP) standards could go some way to addressing the ambiguity around how medicines are packaged, marketed, sold, dosed and consumed in different countries.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze